EMA — authorised 29 July 1998
- Application: EMEA/H/C/000154
- Marketing authorisation holder: CHEPLAPHARM Arzneimittel GmbH
- Local brand name: Xenical
- Indication: Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.
- Status: approved